198 related articles for article (PubMed ID: 36545912)
1. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.
Schmierer K; Wiendl H; Oreja-Guevara C; Centonze D; Chudecka A; Roy S; Boschert U
Neurodegener Dis Manag; 2023 Feb; 13(1):15-21. PubMed ID: 36545912
[TBL] [Abstract][Full Text] [Related]
2. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A
Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
[TBL] [Abstract][Full Text] [Related]
3. The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Neurodegener Dis Manag; 2022 Dec; 12(6):285-293. PubMed ID: 35920065
[TBL] [Abstract][Full Text] [Related]
4. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
[TBL] [Abstract][Full Text] [Related]
5. Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
Schmierer K; Wiendl H; Oreja-Guevara C; Centonze D; Chudecka A; Roy S; Boschert U
Mult Scler; 2022 Nov; 28(13):2151-2153. PubMed ID: 35672923
[No Abstract] [Full Text] [Related]
6. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; di Cantogno EV
Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
[TBL] [Abstract][Full Text] [Related]
7. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Der Walt AV; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri D; Pesch VV; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H;
Neurodegener Dis Manag; 2023 Aug; 13(4):215-221. PubMed ID: 37287269
[TBL] [Abstract][Full Text] [Related]
8. Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
Oh J; Walker B; Giovannoni G; Jack D; Dangond F; Nolting A; Aldridge J; Lebson LA; Leist TP
Neurodegener Dis Manag; 2022 Feb; 12(1):1-7. PubMed ID: 35019731
[TBL] [Abstract][Full Text] [Related]
9. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
Adamec I; Brecl Jakob G; Rajda C; Drulović J; Radulović L; Bašić Kes V; Lazibat I; Rimac J; Cindrić I; Gržinčić T; Abičić A; Barun B; Gabelić T; Gomezelj S; Mesaroš Š; Pekmezović T; Klivényi P; Krbot Skorić M; Habek M
J Neuroimmunol; 2023 Sep; 382():578164. PubMed ID: 37536052
[TBL] [Abstract][Full Text] [Related]
10. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
[TBL] [Abstract][Full Text] [Related]
11. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.
Rieckmann P; Centonze D; Giovannoni G; Hua LH; Oreja-Guevara C; Selchen D; Sørensen PS; Vermersch P; Wiendl H; Salloukh H; Yamout B
Neurodegener Dis Manag; 2023 Feb; 13(1):5-13. PubMed ID: 36278394
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
Rau D; Müller B; Übler S
Adv Ther; 2023 Dec; 40(12):5547-5556. PubMed ID: 37776477
[TBL] [Abstract][Full Text] [Related]
13. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
[TBL] [Abstract][Full Text] [Related]
14. [Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].
Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):73-77. PubMed ID: 35912560
[TBL] [Abstract][Full Text] [Related]
15. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
[TBL] [Abstract][Full Text] [Related]
16. Cladribine Tablets: A Review in Relapsing MS.
Deeks ED
CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
[TBL] [Abstract][Full Text] [Related]
18. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
[TBL] [Abstract][Full Text] [Related]
19. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
[TBL] [Abstract][Full Text] [Related]
20. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
Brownlee W; Amin A; Ashton L; Herbert A
Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
